乳腺癌组织中IL-6与PRL表达及其临床意义

doi:10.13418/j.issn.1001-165x.2018.03.010

中国临床解剖学杂志 ›› 2018, Vol. 36 ›› Issue (3): 288-293.doi: 10.13418/j.issn.1001-165x.2018.03.010

乳腺癌组织中IL-6与PRL表达及其临床意义

高延鑫，　孙景波，　邓云爻，　刘立新，　刘晓珑

南方医科大学第三附属医院普外科，广州 510630

收稿日期:2018-03-23 出版日期:2018-05-25 发布日期:2018-07-04
通讯作者: 刘晓珑，副主任医师，硕士生导师，Tel：020-62784433，E-mail：lxl1979@i. smu. edu.cn
作者简介:高延鑫（1990-），在读硕士，主要从事乳腺癌转移方面的研究，E-mail: gaoyanxin2@i.smu.edu.cn
基金资助:
广州市天河区科技计划项目（201504KW038；201604KW011）

Expression of IL-6 and PRL in breast cancer tissue and its clinical significance

GAO Yan-xin，SUN Jing-bo，DENG Yun-yao，LIU Li-xin，LIU Xiao-long

Department of general surgery，The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China

Received:2018-03-23 Online:2018-05-25 Published:2018-07-04

摘要/Abstract

摘要：

目的　探讨白介素-6（interleukin-6，IL-6）和催乳素（prolactin，PRL）在乳腺浸润性导管癌（breast invasive ductal carcinoma，BIDC）组织中的表达及临床意义。方法　采用免疫组化法对63例乳腺癌及其癌旁组织、17例乳腺纤维瘤中IL-6和PRL的表达进行检测，结合临床病理参数及无事件生存（event free survival，EFS）进行统计学分析。结果　浸润性导管癌组织中IL-6和PRL阳性率均高于癌旁组织及乳腺纤维瘤组织（P均＜0.05）；癌旁组织中IL-6和PRL的表达高于瘤旁组织（P均＜0.05）；IL-6、PRL的表达均与肿瘤大小、TNM分期相关（P均＜0.05）；IL-6与PRL表达呈显著正相关（rs=0.842，P＜0.05）。EFS显示，IL-6、PRL高表达组患者EFS均低于低表达组患者（分别为IL-6，Log- rank= 5.186，P= 0.023；PRL， Log- rank= 5.743，P= 0.017）。单因素Cox风险模型显示，淋巴结转移、TNM分期高、IL-6阳性表达、PRL阳性表达均对患者的EFS有影响。结论　检测乳腺癌中PRL和IL-6的表达有利于其预后诊断；通过缓解病人的紧张、促进情绪调节、改善睡眠质量等因素可在一定程度上降低乳腺癌的发生、进展及不良预后的风险。

关键词: 乳腺肿瘤, 　IL-6, 　PRL, 　免疫组织化学, 　预后

Abstract:

Objective　To investigate the expression of interleukin-6 (IL-6) and prolactin (PRL) in breast invasive ductal carcinoma (BIDC) and its clinical significance. Method　Immunohistochemistry was used to detect the expression of IL-6 and PRL in 63 cases of breast cancer and its paraneoplastic tissues and 17 cases of breast fibroadenoma. The clinical pathological parameters and event-free survival were analyzed statistically. Results　The positive rates of IL-6 and PRL in infiltrating ductal carcinoma were higher than those in adjacent tissues and fibroids (P<0.05). The expressions of IL-6 and PRL in the adjacent tissues were higher than those in paratumor tissues (P<0.05). The expression of IL-6 and PRL were correlated with tumor size and TNM stage (P<0.05). There was a significant positive correlation between IL-6 and PRL expression (rs= 0.842, P<0.05). Event-free survival showed that the event-free survival of patients with high expression of IL-6 and PRL was lower than that of patients with low expression (IL-6, Log- rank= 5.186, P= 0.023; PRL, Log- rank= 5.743, respectively. P= 0.017). The univariate Cox risk model showed that lymph node metastasis, high TNM stage, positive IL-6 expression, and positive PRL expression all had influence on the event-free survival of patients. Conclusion　The detection of PRL and IL-6 expression in breast cancer is beneficial to its prognosis diagnosis; Reducing the patient's stress, promoting emotional regulation, improving sleep quality and other factors can, to some extent, reduce the risk of breast cancer, progression and poor prognosis.

Key words: , Breast tumor, 　IL-6, 　Prolactin, 　Immunohistochemistry, 　Prognosis

高延鑫,孙景波,邓云爻,刘立新,刘晓珑. 乳腺癌组织中IL-6与PRL表达及其临床意义[J]. 中国临床解剖学杂志, 2018, 36(3): 288-293.

GAO Yan-xin，SUN Jing-bo，DENG Yun-yao，LIU Li-xin，LIU Xiao-long. Expression of IL-6 and PRL in breast cancer tissue and its clinical significance[J]. Chinese Journal Of Clinical Anatomy, 2018, 36(3): 288-293.

参考文献

[1] DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(10): 1495-1506.
[2] Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[3] Felipe LJ, Nofech-Mozes S, Bayani J, et al. EMT in breast carcinoma-a review[J]. J Clin Med, 2016, 5(7): E65.

[4] Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells[J]. Oncogene, 2009, 28(33): 2940-2947.
[5] Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer[J]. Eur J Cancer, 2012, 48(1): 85-93.
[6] Olsen J, Kirkeby LT, Olsen J, et al. High interleukin-6 mRNA expression is a predictor of relapse in colon cancer[J]. Anticancer Res, 2015, 35(4): 2235-2240.
[7] Sasser AK, Sullivan NJ, Studebaker AW, et al. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer[J]. FASEB J, 2007, 21(13): 3763-3770.
[8] Clevenger CV, Furth PA, Hankinson SE, et al. The role of prolactin in mammary carcinoma[J]. Endocr Rev, 2003, 24(1): 1-27.
[9] Shiu RP, Murphy LC, Tsuyuki D, et al. Biological actions of prolactin in human breast cancer[J]. Recent Prog Horm Res, 1987, 43: 277-303.
[10]Binart N, Ormandy CJ, Kelly PA. Mammary gland development and the prolactin receptor[J]. Adv Exp Med Biol, 2000, 480: 85-92.
[11] 王庭槐.生理学[M].第3版, 北京：人民卫生出版社, 2015: 555.
[12] Blanco EJ, Carretero-Hernández M, García-Barrado J, et al. The activity and proliferation of pituitary prolactin-positive cells and pituitary VIP-positive cells are regulated by interleukin 6[J]. Histol Histopathol, 2013, 28(12): 1595-1604.
[13] Amin MB, Edge S, Greene FL. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2016.
[14] Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin[J]. Nature, 1986, 324(6092): 73-76.
[15] De Filippo G, Rendina D, Moccia F, et al. Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents[J]. J Endocrinol Invest, 2015, 38(3): 339-343.
[16]Chen X, Wang L, Wang W, et al. B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation[J]. Cancer Sci, 2016, 107(7): 944-954.
[17]Li F, Gu C, Tian F, et al. MiR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression[J]. Oncol Rep, 2016, 35(5): 2859-2865.
[18]Rokavec M, Öner MG, Li H, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis[J]. J Clin Invest, 2014, 124(4): 1853-1867.
[19]Jiang Q, Li Q, Chen H, et al. Scutellaria barbata D. Don inhibits growth and induces apoptosis by suppressing IL-6-inducible STAT3 pathway activation in human colorectal cancer cells[J]. Exp Ther Med, 2015, 10(4): 1602-1608.

乳腺癌组织中IL-6与PRL表达及其临床意义

Expression of IL-6 and PRL in breast cancer tissue and its clinical significance

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

Metrics

本文评价

推荐阅读 0

[1]	孙攀文, 郭永龙, 贾阳阳, 孙昌业, 郭志坤. 大鼠冠状动脉粥样硬化钙化组织与c-kit^＋和sca-1^＋细胞的关系研究[J]. 中国临床解剖学杂志, 2023, 41(4): 453-458.
[2]	熊杨, 陈艳, 魏东, 张琴, 程茂杰, 宋琪. 苦参凝胶对银屑病大鼠皮肤损伤组织病理学及IL-6、PAR-2水平的影响[J]. 中国临床解剖学杂志, 2023, 41(1): 72-76.
[3]	李炽阳, 杨帆, 杨悦, 陆云涛, 周强. CBX3在脑胶质瘤中的表达分析及其对胶质瘤细胞凋亡的抑制作用[J]. 中国临床解剖学杂志, 2022, 40(5): 562-568.
[4]	孙玙, 杨水泉, 胡朝晖, 梁文俊, 何杏玲. 血清铁调素及铁代谢指标与脑出血早期病情及预后的相关性研究[J]. 中国临床解剖学杂志, 2021, 39(3): 355-358.
[5]	葛新江, 　游建军, 　刘晓峰, 　马英. 关节镜辅助MIPPO技术治疗老年Schatzker Ⅱ~Ⅲ型胫骨平台骨折的疗效及预后研究[J]. 中国临床解剖学杂志, 2021, 39(3): 342-345.
[6]	张浩楠, 张林枝, 高炜, 徐彦, 杨雪玲, 于海鹏, 邢文阁, 司同国. 免疫评分在肝癌患者中的预后研究[J]. 中国临床解剖学杂志, 2021, 39(1): 82-89.
[7]	孙晓鹏, 郭康, 郭志坤. 高脂血症大鼠心肌中脂滴分布和H-FABP表达变化[J]. 中国临床解剖学杂志, 2021, 39(1): 49-54.
[8]	李菁, 金玉, 李启阳, 许英卓, 刘超, 肖建英. 蛋白激酶WEE1在胃癌组织中的表达及其临床意义[J]. 中国临床解剖学杂志, 2020, 38(6): 680-684.
[9]	曹志远, 何爱咏, 肖波. 糖尿病足截肢术预后影响因素分析及预后能力评估[J]. 中国临床解剖学杂志, 2020, 38(4): 481-485.
[10]	张虎,杜欣娜,庄莹,孙海燕,樊伟平,赵小芳. 乳腺癌中跨膜蛋白81基因高表达不利于患者预后[J]. 中国临床解剖学杂志, 2018, 36(5): 586-589.
[11]	孙江,李月,牛世贤,黄梦怡,钟玙沄,赵舒祺,罗海华,姜勇,刘靖华. SETD4对脂多糖诱导的AML12细胞IL-6转录的调控作用[J]. 中国临床解剖学杂志, 2018, 36(3): 282-287.
[12]	潘阳建,高源,刘晓珑,孙景波,黄晓萍,刘立新. XKRX在结直肠癌的表达和临床意义[J]. 中国临床解剖学杂志, 2018, 36(2): 202-205.